Department of Neurology, Shanghai People's Liberation Army 85th Hospital, Shanghai 200052, China.
Chin Med J (Engl). 2011 Jan;124(1):106-10.
RNA interference (RNAi) is a potential cure for amyotrophic lateral sclerosis (ALS) caused by dominant, gain-of-function superoxide dismutase 1 (SOD1) mutations. The success of such therapy relies on the functional small interfering RNAs (siRNAs) that can effectively deliver RNAi. This study aimed to design the functional siRNAs targeting ALS-associated mutant alleles.
A modified dual luciferase system containing human SOD1 mRNA target was established to quantify siRNA efficacy. Coupled with validated siRNAs identified in the literature, we analyzed the rationale of siRNA design and subsequently developed an asymmetry rule-based strategy for designing siRNA. We then further tested the effectiveness of this design strategy in converting a naturally symmetric siRNA into functional siRNAs with favorable asymmetry for gene silencing of SOD1 alleles.
The efficacies of siRNAs could vary tremendously by one base-pair position change. Functional siRNAs could target the whole span of SOD1 mRNA coding sequence as well as non-coding region. While there is no distinguishable pattern of the distribution of nucleobases in these validated siRNAs, the high percent of GC count at the last two positions of siRNAs (P18 and P19) indicated a strong effect of asymmetry rule. Introducing a mismatch at position 1 of the 5' of antisense strand of siRNA successfully converted the inactive siRNA into functional siRNAs that silence SOD1 with desired efficacy.
Asymmetry rule-based strategy that incorporates a mismatch into siRNA most consistently enhances RNAi efficacy and guarantees producing functional siRNAs that successfully silence ALS-associated SOD1 mutant alleles regardless target positions. This strategy could also be useful to design siRNAs for silencing other disease-associated dominant, gain-of-function mutant genes.
RNA 干扰 (RNAi) 是治疗由显性、功能获得性超氧化物歧化酶 1 (SOD1) 突变引起的肌萎缩侧索硬化症 (ALS) 的潜在方法。这种疗法的成功依赖于能够有效传递 RNAi 的功能性小干扰 RNA (siRNA)。本研究旨在设计针对与 ALS 相关的突变等位基因的功能性 siRNA。
建立了包含人 SOD1 mRNA 靶标的改良双荧光素酶系统,以定量 siRNA 的功效。结合文献中验证的 siRNA,我们分析了 siRNA 设计的原理,并随后开发了一种基于不对称规则的 siRNA 设计策略。我们进一步测试了这种设计策略将自然对称 siRNA 转化为具有有利不对称性的功能性 siRNA 的效果,以实现 SOD1 等位基因的基因沉默。
siRNA 的功效可能因一个碱基对位置的变化而有很大差异。功能性 siRNA 可以靶向 SOD1 mRNA 编码序列的整个范围以及非编码区。虽然这些验证的 siRNA 中没有可区分的核碱基分布模式,但 siRNA 的最后两个位置(P18 和 P19)的 GC 计数百分比很高,表明不对称规则的影响很大。在 siRNA 反义链 5'端的第 1 位引入错配成功地将无活性的 siRNA 转化为具有所需功效的功能性 siRNA,从而沉默 SOD1。
基于不对称规则的策略,将错配引入 siRNA 最一致地增强了 RNAi 的功效,并保证产生能够成功沉默与 ALS 相关的 SOD1 突变等位基因的功能性 siRNA。该策略也可用于设计沉默其他与疾病相关的显性、功能获得性突变基因的 siRNA。